Resistance of Lenvatinib in Hepatocellular Carcinoma.

Jinhui Guo, Junjun Zhao, Qiuran Xu, Dongsheng Huang

Journal: Current cancer drug targets 2022;22(11):865-878

PMID: 36267045

Abstract

Lenvatinib is a multikinase inhibitor which mainly hinders liver cancer proliferation by inhibiting angiogenesis. In 2018, Lenvatinib was approved for the first-line treatment of patients with advanced hepatocellular carcinoma [HCC] in the United States, the European Union, Japan, and China. Lenvatinib has been established as a sorafenib replacement drug with a higher objective response rate [ORR], longer progression-free survival [PFS], and time to progression [TTP]. Lenvatinib resistance during hepatocellular carcinoma treatment has become increasingly common in recent years. Accordingly, it is necessary to determine factors associated with Lenvatinib resistance and explore solutions. In this review, we sought to explore the drug resistance mechanisms of Lenvatinib in liver cancer and methods to reduce drug resistance and summarized the recent achievements of Lenvatinib in liver cancer treatment.

Address: Qingdao Medical College, Qingdao University, Qingdao, Shandong 266071, China.; Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.; Graduate Department, Bengbu Medical College, Bengbu, Anhui 233030, China.

DOI: 10.2174/1568009622666220428111327

Link outs

Free resources

Medical:

https://medlineplus.gov/livercancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Antineoplastic Agents, Phenylurea Compounds, Quinolines